EAD (TTM)

EAD/share (TTM)

EAD (Quarter)

EAD/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/EAD

Based in Westbury, NY, ACRES Commercial Realty Corp is a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and other commercial real estate-related debt investments. The Company is externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., a private commercial real estate lender exclusively dedicated to nationwide middle market CRE lending with a focus on multifamily, student housing, hospitality, office, industrial and other asset types in top US markets.

ACRES Commercial Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2021 Q4

Years since IPO: 15/15,
EAD Growth: 1/15,
EAD/share Growth: 1/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2022 Q4

Years since IPO: 15/15,
EAD Growth: 1/15,
EAD/share Growth: 1/20,
Dividend Growth: 5/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q1

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
EAD Growth: 6/15,
EAD/share Growth: 11/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's EAD

EAD Growth

Assessment of recent increases in EAD per share, indicating profitability

EAD/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Zefiro has made a key breakthrough by successfully originating carbon credits based on confirmed emissions reductions of 92,956 metric tonnes of CO2 equivalent from a remediation project in Custer County, Oklahoma. Zefiro has also made its first delivery of carbon credits to Mercuria Energy America, LLC to fulfill a pre-sale agreement.

Zefiro Methane Completes First-Ever Sale of Carbon Offsets Originated Under ACR's Orphan Well Methodology

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

UNIONDALE, N.Y. , July 30, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter ended June 30, 2025.

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR SECOND QUARTER 2025

UNIONDALE, N.Y. , July 16, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the second quarter 2025, on Wednesday, July 30, 2025, after the market closes.

ACRES Commercial Realty Corp. to Report Results for Second Quarter 2025

UNIONDALE, N.Y. , June 5, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

Agreement would extend Nexxen's global ACR data exclusivity with VIDAA, while adding display ad monetization exclusivity across VIDAA's media in North America Agreement would extend Nexxen's global ACR data exclusivity with VIDAA, while adding display ad monetization exclusivity across VIDAA's media in North America

Nexxen and VIDAA Sign Non-Binding MOU to Extend and Expand Strategic Partnership

Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory approvals, and establishing new standards of care in gynecological oncology Cash, cash equivalents and marketable securities of $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass.

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

ZEFIRO HAS MADE A KEY BREAKTHROUGH BY SUCCESSFULLY ORIGINATING CARBON CREDITS BASED ON CONFIRMED EMISSIONS REDUCTIONS OF 92,956 METRIC TONNES OF CO2 EQUIVALENT FROM A REMEDIATION PROJECT IN CUSTER COUNTY, OKLAHOMA. ZEFIRO HAS ALSO MADE ITS FIRST DELIVERY OF CARBON CREDITS TO MERCURIA ENERGY AMERICA, LLC TO FULFILL A PRE-SALE AGREEMENT.

ZEFIRO METHANE COMPLETES FIRST-EVER SALE OF CARBON OFFSETS ORIGINATED UNDER ACR'S ORPHAN WELL METHODOLOGY

CONTINUED ADVANCEMENT OF TWO CLINICAL-STAGE ASSETS, BOTH WITH CLINICALLY DEMONSTRATED SINGLE-AGENT ANTI-TUMOR ACTIVITY -- ACR-368 IN A REGISTRATIONAL-INTENT PHASE 2 STUDY IN ENDOMETRIAL CANCER AND ACR-2316 IN A PHASE 1 STUDY IN AP3-PREDICTED TUMOR TYPES

ACRIVON THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

UNIONDALE, N.Y. , JULY 30, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) ("ACR" OR THE "COMPANY"),A REAL ESTATE INVESTMENT TRUST THAT IS PRIMARILY FOCUSED ON ORIGINATING, HOLDING AND MANAGING COMMERCIAL REAL ESTATE MORTGAGE LOANS AND EQUITY INVESTMENTS IN COMMERCIAL REAL ESTATE PROPERTY THROUGH DIRECT OWNERSHIP AND JOINT VENTURES, TODAY REPORTED RESULTS FOR THE QUARTER ENDED JUNE30, 2025.

UNIONDALE, N.Y. , JULY 16, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE:ACR) (THE "COMPANY") ANNOUNCED TODAY THAT IT WILL RELEASE ITS RESULTS FOR THE SECOND QUARTER 2025, ON WEDNESDAY, JULY 30, 2025, AFTER THE MARKET CLOSES.

ACRES COMMERCIAL REALTY CORP. TO REPORT RESULTS FOR SECOND QUARTER 2025

UNIONDALE, N.Y. , JUNE 5, 2025 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP.(NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED CASH DIVIDENDS ON ITS PREFERRED STOCK.

ACRES COMMERCIAL REALTY CORP. DECLARES QUARTERLY CASH DIVIDENDS FOR ITS PREFERRED STOCK

AGREEMENT WOULD EXTEND NEXXEN'S GLOBAL ACR DATA EXCLUSIVITY WITH VIDAA, WHILE ADDING DISPLAY AD MONETIZATION EXCLUSIVITY ACROSS VIDAA'S MEDIA IN NORTH AMERICA AGREEMENT WOULD EXTEND NEXXEN'S GLOBAL ACR DATA EXCLUSIVITY WITH VIDAA, WHILE ADDING DISPLAY AD MONETIZATION EXCLUSIVITY ACROSS VIDAA'S MEDIA IN NORTH AMERICA

NEXXEN AND VIDAA SIGN NON-BINDING MOU TO EXTEND AND EXPAND STRATEGIC PARTNERSHIP

CORPORATE R&D EVENT HIGHLIGHTED POSITIVE ACR-368 DATA IN ENDOMETRIAL CANCER PATIENTS WHO HAD ALL RECEIVED PRIOR ANTI-PD-1 AND PLATINUM-BASED CHEMOTHERAPY CONFIRMED OVERALL RESPONSE RATE (CORR) OF 35% AND MEDIAN DURATION OF RESPONSE (MDOR) >5.6 MONTHS (NOT YET REACHED) OBSERVED IN ONCOSIGNATURE-POSITIVE (BM+) PATIENTS, A MAJORITY OF WHOM WERE REFRACTORY TO LAST PRIOR THERAPY, AND CORR OF 50% AND MDOR >10 MONTHS (NOT YET REACHED) FOR BM+ PATIENTS WHO HAD RELAPSED ON LAST PRIOR THERAPY THREE DOSE ESCALATION COHORTS COMPLETED IN ACR-2316 PHASE 1 TRIAL WITH TUMOR SHRINKAGE OBSERVED ALREADY AT DOSE LEVEL (DL)3, BELOW PROJECTED RECOMMENDED PHASE 2 DOSE AACR PRESENTATION OF ACR-2316 REVEALING MECHANISMS UNDERLYING ITS SUPERIOR PRECLINICAL ACTIVITY WITH POTENT MITOTIC TUMOR CELL DEATH USING AP3 GENERATIVE PHOSPHOPROTEOMICS MANSOOR RAZA MIRZA, M.D. APPOINTED CHIEF MEDICAL OFFICER; ACCOMPLISHED CLINICIAN WITH STELLAR TRACK RECORD OF SUCCESSFULLY LEADING REGISTRATIONAL TRIALS THROUGH REGULATORY APPROVALS, AND ESTABLISHING NEW STANDARDS OF CARE IN GYNECOLOGICAL ONCOLOGY CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $164.8 MILLION AS OF MARCH 31, 2025, EXPECTED TO FUND OPERATIONS INTO THE SECOND QUARTER OF 2027 WATERTOWN, MASS.

ACRIVON THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

UNIONDALE, N.Y. , APRIL 30, 2025 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP. (NYSE:ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS (THE "BOARD") AUTHORIZED AND APPROVED THE CONTINUED USE OF ITS EXISTING SHARE REPURCHASE PROGRAM TO REPURCHASE AN ADDITIONAL $10 MILLION OF THE OUTSTANDING SHARES OF BOTH ITS COMMON AND PREFERRED STOCK.

ACRES COMMERCIAL REALTY CORP. REAUTHORIZES AN ADDITIONAL $10 MILLION SHARE REPURCHASE PROGRAM

UNIONDALE, N.Y. , APRIL 30, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) ("ACR" OR THE "COMPANY"),A REAL ESTATE INVESTMENT TRUST THAT IS PRIMARILY FOCUSED ON ORIGINATING, HOLDING AND MANAGING COMMERCIAL REAL ESTATE MORTGAGE LOANS AND EQUITY INVESTMENTS IN COMMERCIAL REAL ESTATE PROPERTY THROUGH DIRECT OWNERSHIP AND JOINT VENTURES, TODAY REPORTED RESULTS FOR THE QUARTER ENDED MARCH31, 2025.

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FIRST QUARTER 2025

PRESENTATION TO HIGHLIGHT HOW AP3 GENERATIVE PHOSPHOPROTEOMIC ANALYSES UNCOVER HOW ACR-2316 INDUCES MITOTIC AND REPLICATIVE TUMOR CELL DEATH, AND THE MECHANISMS UNDERLYING ITS SUPERIOR POTENCY OBSERVED PRECLINICALLY

ACRIVON THERAPEUTICS TO REVEAL THE MOLECULAR MECHANISMS DRIVING STRONG SINGLE-AGENT ACTIVITY OF ACR-2316, ITS AP3-ENABLED CLINICAL STAGE WEE1/PKMYT1 INHIBITOR, AT THE AACR ANNUAL MEETING 2025

ACRES Commercial Realty

ACR

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR